Clinical trial NCT00970346: Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis
Official title: A Randomised, Double-blind, Placebo-controlled Dose-escalation Phase I Study to Evaluate the Safety and Tolerability of Inhaled Aerosolised OligoG CF-5/20 (G-block Oligosaccharide Derived From Alginate Polysaccharide) in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cystic Fibrosis
Keywords: Digestive System Diseases
Genetic Diseases
Inborn
Respiratory Tract Diseases
Cystic Fibrosis
Lung Disease
Pancreatic Diseases
Lead sponsor: AlgiPharma AS
Sponsor class: INDUSTRY
Collaborators: name: Smerud Medical Research International AS
First posted: 2009-09-02
Enrollment: 26
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Cystic fibrosis (CF) is a disease caused by a mutation in the gene that makes the cystic fibrosis transmembrane regulator protein. As a result mucus stagnation, obstruction and plugging take place in the respiratory and gastrointestinal tract, the biliary and pancreatic duct, and in the reproductive system. The objective of this study is to determine the safety and tolerability of 3 days of daily dosing of OligoG CF-5/20 versus placebo in healthy volunteers.


Eligibility criteria: Inclusion Criteria:

* Healthy, male subjects aged 18 to 65 years inclusive
* Normal pulmonary function; i.e. FEV1 ≥ 80% of predicted (for age, sex, height and race) and FEV1/FVC ratio ≥ 0.7
* Subject's pre -study physical examination, vital signs and electrocardiogram (ECG) are normal or do not show any clinically significant abnormalities as determined by the investigator
* Subject's pre - study laboratory screen are normal or, if outside of the laboratory reference range, not considered clinically significant

Exclusion Criteria:

* History of any clinically relevant chronic respiratory disorder, including asthma
* Current smoker or smoked within the last 12 months
* History of significant drug or alcohol abuse (defined by the investigator). Subjects with a positive screen for alcohol or drugs of abuse at screening/admission will be excluded from participation in the study.
* Subject who has inhaled any drug in the last 30 days prior to Day 1
* Subject who has received one or more days of systemic pharmacological treatment in the 14 days immediately prior to Day 1
* Participation in a New Chemical Entity clinical study within the previous 16 weeks or a marketed drug clinical study within the previous 12 weeks
* Subjects with a clinically relevant history of significant hepatic, renal, endocrine, cardiac, nervous, psychiatric, gastrointestinal, pulmonary, haematological or metabolic disorder

Primary outcomes:
measure: To determine the safety and local tolerability of multiple dose administration of inhaled alginate oligosaccharide (OligoG CF-5/20) fragment in healthy volunteers, particular emphasis will be put on pulmonary functioning and pulmonary adverse events.
timeFrame: 3 days dosing
Secondary outcomes:
Other outcomes:
Locations:
city: Merthyr Tydfil
country: United Kingdom
Study officials:
affiliation: Simbec Research
name: Salvatore Febbraro
role: PRINCIPAL_INVESTIGATOR
References: